You are here

Article Text

Article menu
Download PDFPDF
Electronic pages
Pharmacological interventions
More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia
  1. Shahin Akhondzadeh,
  2. Ehsan Moazen-Zadeh
  1. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
  1. Correspondence to Professor Shahin Akhondzadeh, Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran 13337, Iran; s.akhond{at}neda.net
View Full Text

http://dx.doi.org/10.1136/eb-2016-102500

Statistics from Altmetric.com

    ABSTRACT FROM: Barnes TR, Leeson VC, Paton C, et al. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technol Assess 2016;20:1–46.OpenUrlCrossRefPubMed

    What is already known on this topic?

    Persistent negative symptoms which do not respond to antipsychotic regimens are experienced by 15–20% of patients with schizophrenia.1 Antidepressants have been the most studied augmentation strategy in these patients;2 however, previous findings are inconsistent in terms of their potential benefits.

    Methods of the study

    In this double-blind, placebo-controlled, parallel-group, 15-centre pragmatic trial, 62 patients with schizophrenia with persistent primary negative symptoms were randomised in a 1:1 ratio to receive either citalopram (20 mg/day) or placebo as an adjunctive therapy to the baseline ongoing stable dose of second generation antipsychotic treatment for 48 weeks. Patients were excluded in case of receiving any antidepressants or any drug that risked interaction with citalopram at baseline. Between-group differences in …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/